These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6107332)

  • 1. The potential of GABA-mimetics in the therapy of extrapyramidal disorders.
    Bartholini G; Lloyd KG
    J Neural Transm Suppl; 1980; (16):229-38. PubMed ID: 6107332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neuropathology of GABA neurons in extrapyramidal disorders.
    Lloyd KG
    J Neural Transm Suppl; 1980; (16):217-27. PubMed ID: 6448916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
    Bartholini G
    Schweiz Arch Neurol Neurochir Psychiatr; 1979; 125(2):265-9. PubMed ID: 45343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the new gamma-aminobutyric acid agonist SL 76 002 on striatal acetylcholine: relation to neuroleptic-induced extrapyramidal alterations.
    Bartholini G; Scatton B; Zivkovic B
    Adv Biochem Psychopharmacol; 1980; 24():207-13. PubMed ID: 6105775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotransmitter interactions related to central dopamine neurons.
    Lloyd KG
    Essays Neurochem Neuropharmacol; 1978; 3():129-207. PubMed ID: 30628
    [No Abstract]   [Full Text] [Related]  

  • 6. Significance of neurochemical parameters in the preclinical evaluation of neuroleptic drugs.
    Cattabeni F; Galli CL; Groppetti A; Racagni G
    Pharmacol Ther B; 1979; 5(1-3):563-70. PubMed ID: 40267
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use of the methylxanthines, caffeine and theophylline, in the treatment of extrapyramidal disorders caused by treatment with neuroleptics. Development of a therapeutic hypothesis].
    Casas M; Torrens M; Duro P; Pinet C; Alvarez E; Udina C
    Encephale; 1989; 15 Spec No():177-80. PubMed ID: 2568253
    [No Abstract]   [Full Text] [Related]  

  • 8. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.
    Marsden CD; Jenner P
    Psychol Med; 1980 Feb; 10(1):55-72. PubMed ID: 6104342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogenetic treatment of various hereditary extrapyramidal disorders with new drugs].
    Markowa ED; Hausmanowa-Petrusewicz I; Alijewa LM; Friedman A; Insarowa NG
    Neurol Neurochir Pol; 1981; 15(4):403-6. PubMed ID: 7329507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finger tremor and extrapyramidal side effects of neuroleptic drugs.
    Collins P; Lee I; Tyrer P
    Br J Psychiatry; 1979 May; 134():488-93. PubMed ID: 38876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
    Sayers AC; Bürki HR; Ruch W; Asper H
    Psychopharmacology (Berl); 1976 Dec; 51(1):15-22. PubMed ID: 13446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing concepts of nigral dopamine system function within the basal ganglia: relevance to extrapyramidal disorders.
    Bunney BS; Grace AA; Hommer DW
    J Neural Transm Suppl; 1980; (16):17-23. PubMed ID: 6107330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.
    Bezchlibnyk-Butler KZ; Remington GJ
    Can J Psychiatry; 1994 Mar; 39(2):74-84. PubMed ID: 7908605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium therapy for neuroleptic-induced extrapyramidal symptoms.
    Fernando ML; Manchanda R
    Br J Psychiatry; 1988 May; 152():722-3. PubMed ID: 2901889
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination therapy of extrapyramidal disease with trihexyphenidyl and L-dopa: an electromyographic study with specific reference to tremor.
    Hökendorf H
    J Int Med Res; 1979; 7(1):19-28. PubMed ID: 421963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs.
    McEvoy JP
    J Clin Psychopharmacol; 1983 Oct; 3(5):288-302. PubMed ID: 6138370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology.
    Allen RM
    Clin Neuropharmacol; 1983; 6 Suppl 1():S64-73. PubMed ID: 6196112
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacology of extrapyramidal movement disorders.
    Klawans HL
    Monogr Neural Sci; 1973; 2():1-136. PubMed ID: 4271860
    [No Abstract]   [Full Text] [Related]  

  • 20. [Correction of an extrapyramidal neuroleptic syndrome with tryptophan and the dynamics of its concentration in the blood of patients].
    Balakleevskiĭ AI; Mitiukova TA; Vazhenin MM; Gaĭduk FM
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(2):95-7. PubMed ID: 6112836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.